Acquisition Opportunity DxRG was acquired by The IMA Group in October 2021, indicating a potential alignment with a larger CRO network. This presents a sales opportunity to engage via IMA Group’s Clinical Research Division to expand site utilization, multi-therapeutic trials, and geographic reach.

Small to Mid Size With 11-50 employees and revenue under one million, Diagnostics Research Group operates as a lean, agile site. A focused outreach can emphasize cost-effective trial participation, streamlined onboarding, and personalized site support to win faster study starts.

Therapeutic Breadth DxRG’s expertise spans vaccines, medical devices, internal medicine, allergies, pulmonary, and fatty liver diseases. This breadth enables cross-sell opportunities for CRO services across multiple trial types and phases to attract sponsors seeking diverse capabilities.

Geographic Focus Located in San Antonio, TX, DxRG can complement a national CRO footprint by offering regional patient access, site diversity, and localized regulatory execution. Target sponsors with site-feasibility needs or studies prioritizing regional enrollment.

Digital Footprint Existing tech stack includes analytics, tracking pixels, and standard web tech. Leverage performance marketing and data-driven outreach to identify trial opportunities, optimize site fit criteria, and personalize engagement with decision-makers at sponsor and CRO organizations.